The phase III MONALEESA-7 trial specifically focused on pre-/perimenopausal patients with HR+/HER2− advanced breast cancer and studied ribociclib plus endocrine therapy (ET) vs. placebo plus ET. This evidence concerns the gene HR and breast cancer.